Our multifunctional nano-technology carrier platform harnesses the physical (magnetic, electromagnetic and acoustic)and chemical properties of graphene to generate a diversified product pipeline for diagnostic, therapeutic and regenerative medicine. Graphene's properties "actively" enhances the overall attributes of the constructs rather than serving as a passive carrier.

 

 

Fundamental Attributes of Our Platforms:

 

  • Versatile carrier or scaffold for variety of medical interesting atoms and molecules. 

  • Allows multi-modal clinical and molecular imaging over various length and time scales.

  • Facilates stimulus responsive therapeutics and tissue engineering. 

 

 

ManGraDex

PLATFORM VALUE PROPOSITION:

  • Modular platform for multimodal clinical and molecular imaging.

  • Detectable by magnetic resonance, photoacoustic, and Raman imaging.

  • Suitable for whole body screening of vital organs or vascular imaging.

  • Could facilitate improved image-guided pre-operative staging and intraoperative procedures (e.g. cancer staging and resection).

 

CURRENT STATUS:

  • Conducting investigational new drug (IND)- enabling preclinical studies to assess its efficacy as a long circulating MRI contrast agent for unserved and underserved renal and cardiovascular patient population. 

  • Conducting preclinical studies to assess its efficacy  for photoacoustic imaging of sentinel lymph nodes for breast cancer.

  • Conducting preclinical studies to assess its efficacy for molecular breast cancer screening by MRI (significantly improved specificity).

Nano-GenXb

PLATFORM VALUE PROPOSITION:

  • Modular platform for image-guided drug and gene delivery.

  • Promotes multivalent ligand−cell receptor interactions for enhanced delivery.

  • Allows increased drug or gene-loading capacity.

  • Facilitates stimulus-responsive controlled drug or gene release inside target cells.

  • Enables real-time tracking by multimodal imaging systems.

 

CURRENT STATUS:

  • Completed non-GLP safety pharmacology studies in small animals.

  • Scale up and GLP manufacturing in progress.

  • GLP safety pharmacology studies planned in first quarter of 2017.

  • Conducting preclinical efficacy studies for image-guided delivery of drugs for human papiloma virus (HPV)-induced head and neck cancer.

COLLABORATORS:

  • Dr. John Haley and Dr. Kenneth Shroyer, Stony Brook University
    Conducting preclinical efficacy studies for image-guided delivery of CRISPR/Cas9 constructs to treat Herpesvirus infections.

  • Dr. Laurie Krug, Stony Brook University
    Conducting preclinical efficacy studies for image-guided delivery of
    microRNAs to treat breast cancer metastases.

  • Dr. Vivek Mittal, Weill Cornell and Mircan Therapeutics 
    Conducting preclinical efficacy studies for image-guided delivery of myelin

      basic protein nucleic acid therapeutics to treat Alzheimer’s disease.

  • Dr. William Van Nostrond, Stony Brook University and Gyrus Pharmaceuticals

GraFix

PLATFORM VALUE PROPOSITION:

  • Modular three dimensional all carbon implantable graft substitute (porous scaffold) for tissue engineering.

  • Generates biophysical stimulus, rather than biochemical cue to affect the differentiation of stem cells.

  • Facilitates controlled release of biologics into the regenerating tissue.

  • Allows real time monitoring of anatomical and physiological changes during the tissue regeneration process by multimodal imaging.

 

CURRENT STATUS:

  • Conducting preclinical studies to assess its safety and efficacy as a stimulus-responsive tissue engineering scaffold to treat and monitor the process of regeneration in open fractures. 

  • Conducting preclinical studies to assess its safety and efficacy as a as a stimulus-responsive tissue engineering scaffold to treat and monitor the process of regeneration in burn wounds. 

Our Platform Technology

© Theragnostic Technologies, Inc. 2019

 info@theragnostictechnologies.com

* Disclaimer:  Our products and technologies are currently not available for clinical use. FDA or other regulatory agencies have not evaluated the statements on this website regarding our products and technologies.